Rates and Predictors of Early Discontinuation of Metformin, Placebo, and Endocrine Therapy Among Patients With Hormone Receptor–Positive Early-Stage Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)
Breast Cancer Res Treat 2023 Jul 01;200(1)93-102, DL Hershman, BE Chen, C Sathe, WR Parulekar, J Lemieux, JA Ligibel, KA Gelmon, TJ Whelan, PJ GoodwinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.